|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 153.6 USD | +3.38% |
|
+18.58% | -14.85% |
| Apr. 23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
| Apr. 23 | BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise | MT |
BeiGene, Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 2,458.78 million compared to USD 1,415.92 million a year ago. Net loss was USD 881.71 million compared to USD 2,003.82 million a year ago.
Basic loss per share from continuing operations was USD 8.45 compared to USD 19.37 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.85% | 16.05B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B | |
| -24.71% | 8.24B |
BEIGENE, LTD. 
